DK3123381T3 - Sammensætninger og fremgangsmåder relateret til diagnose af prostatacancer - Google Patents

Sammensætninger og fremgangsmåder relateret til diagnose af prostatacancer Download PDF

Info

Publication number
DK3123381T3
DK3123381T3 DK15768735.1T DK15768735T DK3123381T3 DK 3123381 T3 DK3123381 T3 DK 3123381T3 DK 15768735 T DK15768735 T DK 15768735T DK 3123381 T3 DK3123381 T3 DK 3123381T3
Authority
DK
Denmark
Prior art keywords
diagnosis
compositions
prostate cancer
methods related
methods
Prior art date
Application number
DK15768735.1T
Other languages
Danish (da)
English (en)
Inventor
Vincent Linder
Kim Pettersson
Timo Lovgren
Hans Lilja
Peter T Scardino
Andrew J Vickers
David Steinmiller
Original Assignee
Opko Diagnostics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Diagnostics Llc filed Critical Opko Diagnostics Llc
Application granted granted Critical
Publication of DK3123381T3 publication Critical patent/DK3123381T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Primary Health Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)
DK15768735.1T 2014-03-28 2015-03-27 Sammensætninger og fremgangsmåder relateret til diagnose af prostatacancer DK3123381T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461972099P 2014-03-28 2014-03-28
PCT/US2015/023096 WO2015148979A1 (en) 2014-03-28 2015-03-27 Compositons and methods related to diagnosis of prostate cancer

Publications (1)

Publication Number Publication Date
DK3123381T3 true DK3123381T3 (da) 2023-11-27

Family

ID=54196462

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15768735.1T DK3123381T3 (da) 2014-03-28 2015-03-27 Sammensætninger og fremgangsmåder relateret til diagnose af prostatacancer

Country Status (24)

Country Link
US (2) US11761962B2 (enExample)
EP (2) EP3299977A1 (enExample)
JP (3) JP6775488B2 (enExample)
KR (1) KR102505543B1 (enExample)
CN (2) CN114740202A (enExample)
AR (1) AR099883A1 (enExample)
AU (1) AU2015237270B2 (enExample)
CA (1) CA2944001C (enExample)
CL (1) CL2016002419A1 (enExample)
DE (1) DE202015009668U1 (enExample)
DK (1) DK3123381T3 (enExample)
EA (1) EA201691952A1 (enExample)
ES (1) ES2964706T3 (enExample)
FI (1) FI3123381T3 (enExample)
HU (1) HUE065029T2 (enExample)
IL (2) IL247981B (enExample)
MX (2) MX392384B (enExample)
MY (1) MY192513A (enExample)
PE (1) PE20170298A1 (enExample)
PL (1) PL3123381T3 (enExample)
PT (1) PT3123381T (enExample)
SG (2) SG11201608035UA (enExample)
TW (1) TWI687688B (enExample)
WO (1) WO2015148979A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2687620T3 (es) 2007-05-04 2018-10-26 Opko Diagnostics, Llc Dispositivo y método para análisis en sistemas microfluídicos
DK2391451T3 (en) 2009-02-02 2018-10-15 Opko Diagnostics Llc STRUCTURES FOR MANAGING LIGHT INTERACTION WITH MICROFLUIDIC DEVICES
SG11201406213WA (en) 2012-03-05 2014-11-27 Arctic Partners Ab Oy Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
US12326453B2 (en) * 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
EP3253800B1 (en) 2015-03-27 2021-03-03 Opko Diagnostics, LLC Prostate antigen standards and uses thereof
US11332543B2 (en) 2015-10-05 2022-05-17 Fredax Ab Antibody polypeptides and uses thereof
WO2017100457A1 (en) 2015-12-11 2017-06-15 Opko Diagnostics, Llc Fluidic systems involving incubation samples and/or reagents
CA3006882C (en) 2015-12-29 2023-11-28 Opko Diagnostics, Llc Fluid collection device and related methods
US20190355473A1 (en) * 2017-01-08 2019-11-21 Henry M. Jackson Foundation For The Advancement Of Military Medicine Systems and methods for using supervised learning to predict subject-specific pneumonia outcomes
KR102052398B1 (ko) 2018-04-18 2019-12-05 (주)유로테크 전립선암 진단용 바이오마커 및 이의 용도
WO2020205204A1 (en) 2019-04-03 2020-10-08 Opko Diagnostics, Llc Methods for the detection of prostate cancer
EP4611001A3 (en) * 2019-10-11 2025-11-19 C The Signs Limited Diagnostic tool
KR102730255B1 (ko) * 2022-08-12 2024-11-15 (주)맥시온 암 진단용 다중 바이오마커 및 이의 용도
CN118629514B (zh) * 2024-08-08 2024-10-29 上海橙帆医药有限公司 序列免疫原性预测方法、装置、电子设备及存储介质

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
US5516639A (en) 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
EP0635575A1 (en) 1993-07-22 1995-01-25 Wallac Oy Monoclonal antibodies against epitopes found in free but not in alpha-1-antichmotrypsin complexed prostate specific antigen
ATE263962T1 (de) 1993-10-28 2004-04-15 I Stat Corp Vorrichtung zur abnahme und einleitung von flüssigkeitsproben
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5585069A (en) 1994-11-10 1996-12-17 David Sarnoff Research Center, Inc. Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis
US5614372A (en) 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
JPH11510601A (ja) 1995-08-03 1999-09-14 アクゾ・ノベル・エヌ・ベー 診断装置
US6143509A (en) 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
WO1997039351A1 (en) 1996-04-12 1997-10-23 Carter Herbert B Novel methods for the prediction and early detection of prostatic adenocarcinoma
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
US5945289A (en) 1996-12-20 1999-08-31 Lehrer; Steven Method for detecting prostate cancer by apolipoprotein E (Apo-E) genotyping
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
SE9704934D0 (sv) 1997-12-30 1997-12-30 Pharmacia & Upjohn Diag Ab Analysförfarande med tillsättning i två eller flera positioner
FI980488A7 (fi) 1998-03-04 1999-09-05 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
FR2780791B1 (fr) 1998-07-03 2000-09-01 Bio Merieux Methode de depistage ou de diagnostic d'un adenocarcinome ou d'une pathologie benigne de la prostate et procede de mise en oeuvre
JP4495349B2 (ja) 1999-01-28 2010-07-07 ジェン−プローブ・インコーポレーテッド 癌の遺伝マーカーを生物学的サンプルにおいて検出するための核酸配列
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US7211397B2 (en) 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
US6136549A (en) 1999-10-15 2000-10-24 Feistel; Christopher C. systems and methods for performing magnetic chromatography assays
FI20002127A0 (fi) 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
EP1328342A4 (en) 2000-10-10 2006-03-15 Aviva Biosciences Corp INTEGRATED BIOCHIP SYSTEM FOR SAMPLE PREPARATION AND ANALYSIS
CA2428011A1 (en) 2000-11-20 2002-06-13 Eastern Virginia Medical School Methods and devices for the quantitative detection of prostate specific membrane antigen and other prostatic markers
US20040219163A1 (en) 2001-10-03 2004-11-04 Frelinger John G. Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
WO2003048736A2 (en) 2001-12-05 2003-06-12 University Of Washington Microfluidic device and surface decoration process for solid phase affinity binding assays
US20030235816A1 (en) 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
US20050272052A1 (en) 2002-04-09 2005-12-08 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
WO2003100425A1 (en) 2002-05-28 2003-12-04 Jokoh Co.,Ltd Immunological chromatograph method test slip reading/quantitative determination device
NZ562192A (en) 2002-08-06 2009-07-31 Ciphergen Biosystems Inc Use of biomarkers for detecting ovarian cancer
US20040115794A1 (en) 2002-12-12 2004-06-17 Affymetrix, Inc. Methods for detecting transcriptional factor binding sites
ES2427853T3 (es) * 2003-02-07 2013-11-04 Diagnocure Inc. Procedimiento para detectar cáncer de próstata en una muestra
US7461048B2 (en) 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US20060269971A1 (en) 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer
EP1535667A1 (en) 2003-11-28 2005-06-01 Sysmex Corporation Analyzer, assay cartridge and analyzing method
AU2003292497A1 (en) 2003-12-10 2005-06-29 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A modular biochip assembly
AU2004312893B2 (en) 2003-12-31 2010-06-17 President And Fellows Of Harvard College Assay device and method
US8030057B2 (en) 2004-01-26 2011-10-04 President And Fellows Of Harvard College Fluid delivery system and method
ES2439225T3 (es) 2004-01-26 2014-01-22 President And Fellows Of Harvard College Sistema y método para el suministro de fluidos
TW200538734A (en) 2004-03-12 2005-12-01 Aureon Biosciences Corp Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
EP1747466A2 (en) * 2004-05-11 2007-01-31 Baylor College Of Medicine Method to predict prostate cancer
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
AU2005278136A1 (en) 2004-08-02 2006-03-02 Children's Medical Center Corporation Platelet biomarkers for cancer
CA2580494A1 (en) 2004-09-17 2006-03-30 The Johns Hopkins University Biomarkers for breast cancer
US8663600B2 (en) 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
WO2006122311A2 (en) 2005-05-11 2006-11-16 The Trustees Of The University Of Pennsylvania Microfluidic chip
US20070065954A1 (en) 2005-09-15 2007-03-22 Minoru Taya Surface plasmon resonance biosensor system for detection of antigens and method for determining the presence of antigens
US8409794B2 (en) 2006-03-24 2013-04-02 Phenomenome Discoveries Inc. Biomarkers useful for diagnosing prostate cancer, and methods thereof
JP2009540852A (ja) 2006-07-03 2009-11-26 エグゾニ・テラピューティック・ソシエテ・アノニム 前立腺特異的な転写物ならびに前立腺癌の治療および診断におけるその使用
CN1973778A (zh) 2006-12-08 2007-06-06 南京大学 胃癌术后严重并发症风险度的预测方法
JP5523108B2 (ja) 2006-12-22 2014-06-18 ファディア・アクチボラグ 新規アレルゲンとしての前立腺カリクレイン
ES2687620T3 (es) 2007-05-04 2018-10-26 Opko Diagnostics, Llc Dispositivo y método para análisis en sistemas microfluídicos
WO2008140774A2 (en) * 2007-05-08 2008-11-20 Picobella Llc Methods for diagnosing and treating prostate and lung cancer
CN101329343A (zh) 2007-06-19 2008-12-24 天津迪爱盟生物技术有限公司 新一代早期诊断前列腺癌试剂盒及其制备方法和检测方法
WO2009029550A2 (en) 2007-08-24 2009-03-05 Singulex, Inc. Highly sensitive system and methods for analysis of prostate specific antigen (psa)
CN101377500A (zh) 2007-08-31 2009-03-04 北京科美东雅生物技术有限公司 游离前列腺特异性抗原化学发光免疫分析测定试剂盒及其制备方法
JP5272011B2 (ja) 2007-10-22 2013-08-28 セントビンセンツ ホスピタル シドニー リミテッド 予後判定の方法
WO2009085196A1 (en) 2007-12-21 2009-07-09 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
JP5028697B2 (ja) 2008-02-18 2012-09-19 富士フイルム株式会社 吸引シリンジ及び内視鏡用吸引シリンジ
US20110065605A1 (en) 2008-05-14 2011-03-17 Eth Zurich Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
FR2934698B1 (fr) 2008-08-01 2011-11-18 Commissariat Energie Atomique Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede.
AU2009308124B2 (en) 2008-10-20 2014-12-11 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same
WO2010065940A1 (en) 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
EP2376226B1 (en) 2008-12-18 2018-09-12 Opko Diagnostics, LLC Improved reagent storage in microfluidic systems and related articles and methods
WO2010075446A1 (en) 2008-12-23 2010-07-01 Soar Biodynamics, Ltd. Methods and systems for prostate health monitoring
US20120022793A1 (en) 2009-01-19 2012-01-26 Miraculins, Inc. Biomarkers for the diagnosis of prostate cancer in a non-hypertensive population
DK2391451T3 (en) 2009-02-02 2018-10-15 Opko Diagnostics Llc STRUCTURES FOR MANAGING LIGHT INTERACTION WITH MICROFLUIDIC DEVICES
JP2010243406A (ja) 2009-04-08 2010-10-28 F Hoffmann La Roche Ag Ａｆｐおよびｐｉｖｋａ−ｉｉの測定値を特徴値とした識別関数を利用する、肝臓癌および慢性肝疾患の病態進行度の検出方法
NZ596054A (en) 2009-05-01 2013-07-26 Genomic Health Inc Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
EP3296743A1 (en) * 2009-06-04 2018-03-21 Metanomics Health GmbH Methods for diagnosing prostate carcinomas
WO2011027310A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
WO2011027308A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
KR101141190B1 (ko) * 2009-10-19 2012-06-13 중앙대학교 산학협력단 전립선암에 대한 바이오마커 및 이를 이용한 전립선암 진단
WO2011111007A2 (en) * 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
CA2795215C (en) 2010-04-16 2018-11-06 Opko Diagnostics, Llc Systems and devices for analysis of samples
WO2012029080A1 (en) 2010-08-30 2012-03-08 Decode Genetics Ehf Sequence variants associated with prostate specific antigen levels
BRPI1100857A2 (pt) 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
WO2012129408A2 (en) 2011-03-22 2012-09-27 The Johns Hopkins University Biomarkers for aggressive prostate cancer
WO2012170776A2 (en) 2011-06-09 2012-12-13 Quanterix Corporation Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
JP6072686B2 (ja) 2011-07-21 2017-02-01 和光純薬工業株式会社 血漿中アミノ酸分析用標準液
RU2606773C2 (ru) 2011-10-28 2017-01-10 Фредакс Аб Терапевтические средства и их применение
US20150044666A1 (en) 2012-01-13 2015-02-12 Iris International Inc. Non-equilibrium two-site assays for linear, ultrasensitive analyte detection
SG11201406213WA (en) * 2012-03-05 2014-11-27 Arctic Partners Ab Oy Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
CA2871877A1 (en) * 2012-05-16 2013-11-21 Phadia Ab Method for indicating the presence or non-presence of prostate cancer
CN104583422A (zh) 2012-06-27 2015-04-29 博格有限责任公司 标志物在诊断和治疗前列腺癌中的用途
CN102818892B (zh) 2012-08-16 2015-02-18 北京恩济和生物科技有限公司 一种前列腺特异性抗原检测试剂盒及其制备方法
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
BR112015011359B1 (pt) 2012-11-20 2022-12-06 Phadia Ab Método baseado em uma combinação redundantemente designada de dados para indicar uma presença ou não presença de câncer de próstata agressivo (pca) em um indivíduo, dispositivo de ensaio e kit de teste
EP2922970B1 (en) 2012-11-20 2018-08-08 Phadia AB Prognostic method for individuals with prostate cancer
BR112016011025B1 (pt) 2013-11-19 2024-01-23 Fredax Ab Polipeptídeos anticorpo com especificidade de ligação para calicreina-2 humana (hk2), composição farmacêutica que os compreende e molécula de ácido nucleico
AU2015230017B2 (en) 2014-03-11 2021-06-17 A3P Biomedical Ab Method for detecting a solid tumor cancer
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
WO2016145331A1 (en) 2015-03-12 2016-09-15 Thermo Finnigan Llc Methods for data-dependent mass spectrometry of mixed biomolecular analytes
EP3253800B1 (en) 2015-03-27 2021-03-03 Opko Diagnostics, LLC Prostate antigen standards and uses thereof
HK1247824A1 (zh) 2015-04-29 2018-10-05 欧普科诊断有限责任公司 用於主动监控前列腺癌的组合物和方法
US20190072555A1 (en) 2017-08-14 2019-03-07 Opko Diagnostics, Llc Multiplex assays for evaluating prostate cancer status
WO2019221930A1 (en) 2018-05-16 2019-11-21 Opko Diagnostics, Llc Methods for detecting prostate cancer pathology associated with adverse outcomes

Also Published As

Publication number Publication date
PL3123381T3 (pl) 2024-02-26
WO2015148979A1 (en) 2015-10-01
AR099883A1 (es) 2016-08-24
FI3123381T3 (fi) 2023-11-27
EP3123381A1 (en) 2017-02-01
HUE065029T2 (hu) 2024-04-28
ES2964706T3 (es) 2024-04-09
JP2017515127A (ja) 2017-06-08
JP6775488B2 (ja) 2020-10-28
JP2023017841A (ja) 2023-02-07
PE20170298A1 (es) 2017-04-18
US20230393137A1 (en) 2023-12-07
IL280039B (en) 2021-12-01
PT3123381T (pt) 2023-12-22
BR112016022407A2 (pt) 2017-12-12
WO2015148979A8 (en) 2016-01-07
CA2944001A1 (en) 2015-10-01
IL280039A (en) 2021-03-01
JP7506131B2 (ja) 2024-06-25
CN106663149A (zh) 2017-05-10
IL247981A0 (en) 2016-11-30
AU2015237270A1 (en) 2016-10-20
US20160025732A1 (en) 2016-01-28
CL2016002419A1 (es) 2017-03-31
TW201621320A (zh) 2016-06-16
MX392384B (es) 2025-03-24
IL247981B (en) 2021-02-28
JP7256781B2 (ja) 2023-04-12
KR102505543B1 (ko) 2023-03-02
CA2944001C (en) 2023-08-15
US11761962B2 (en) 2023-09-19
CN114740202A (zh) 2022-07-12
MX2022002365A (es) 2022-04-06
AU2015237270B2 (en) 2021-09-09
MY192513A (en) 2022-08-24
TWI687688B (zh) 2020-03-11
EP3299977A1 (en) 2018-03-28
MX2016012667A (es) 2017-01-09
KR20170008729A (ko) 2017-01-24
DE202015009668U1 (de) 2019-01-21
SG10201808585TA (en) 2018-11-29
EP3123381A4 (en) 2018-02-21
EP3123381B1 (en) 2023-10-11
SG11201608035UA (en) 2016-10-28
JP2021009157A (ja) 2021-01-28
EA201691952A1 (ru) 2017-05-31

Similar Documents

Publication Publication Date Title
DK3123381T3 (da) Sammensætninger og fremgangsmåder relateret til diagnose af prostatacancer
DK3234133T3 (da) Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
DK3189082T3 (da) Anti-pd-l1-konjugater til behandling af tumorer
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3145493T3 (da) Fremgangsmåder og sammensætninger vedrørende exosomer
DK3119808T3 (da) Antistofsammensætninger til tumorbehandling
DK3126394T3 (da) Anti-OX40-antistoffer og fremgangsmåder til anvendelse
DK3137506T3 (da) Sammensætninger og fremgangsmåder relateret til genmanipulerede fc-konstrukter
DK3240801T3 (da) Kombinationstumorimmunterapi
DK3221363T3 (da) Antistoffer mod cd73 og anvendelser deraf
IL251890A0 (en) Combination immunotherapy approach for treatment of cancer
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
HUE066839T2 (hu) Eljárások kardiovaszkuláris kockázat csökkentésére
DK3209696T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK3089971T3 (da) Forbindelser og fremgangsmåder til anvendelse
DK3194564T3 (da) Trichodermasammensætninger og anvendelsesfremgangsmåder
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
DK3467111T3 (da) LNCRNAS til terapi og diagnose af hjertehypertrofi
DK3230481T3 (da) Ferritisk legering
EP3690063C0 (en) DIAGNOSIS OF LUNG CANCER
DK3321645T3 (da) Ultralydsmåler
SG11201701076TA (en) Diagnosis of cancer
EP3134147C0 (en) WASHING PRODUCT FOR INTIMATE USE
DK3190964T3 (da) Spirometer
DK3172497T3 (da) Vandvarmer og anvendelser af denne